ONCY · Oncolytics Biotech Inc. Common Stock
View on chartInsiders & Stakes
| Bernd R. Seizinger Director | ▲ Buy | Open Market | 566,991 Shares held | 2/12/2026 | View profile |
| Wayne Pisano Director | ▲ Buy | Open Market | 492,414 Shares held | 2/12/2026 | View profile |
| Kirk Look Chief Financial Officer | ▲ Buy | Open Market | 287,515 Shares held | 2/12/2026 | View profile |
| Thomas Charles Heineman Chief Medical Officer | ▲ Buy | Open Market | 282,818 Shares held | 2/12/2026 | View profile |
| Allison Hagerman VP, Product Development | ▲ Buy | Open Market | 115,059 Shares held | 2/12/2026 | View profile |
| Jared Kelly Chief Executive Officer | ▲ Buy | Open Market | 114,050 Shares held | 3/12/2026 | View profile |
| Deborah Margaret Brown Director | ▲ Buy | Open Market | 109,851 Shares held | 2/12/2026 | View profile |
| Patricia S. Andrews Director | ▲ Buy | Open Market | 78,128 Shares held | 2/12/2026 | View profile |
| Andrew Aromando Chief Business Officer | ▲ Buy | Open Market | 55,100 Shares held | 2/11/2026 | View profile |
| James T. Parsons Director | ▲ Buy | Open Market | 41,849 Shares held | 3/11/2026 | View profile |
Transaction History
| Jared Kelly | ▲ Buy | Open Market | 5,050 | $5K | 3/12/2026 |
| James T. Parsons | ▲ Buy | Open Market | 10,000 | $10K | 3/11/2026 |
| Jared Kelly | ▲ Buy | Open Market | 29,500 | $25K | 2/12/2026 |
| Kirk Look | ▲ Buy | Open Market | 12,000 | $10K | 2/12/2026 |
| Wayne Pisano | ▲ Buy | Open Market | 30,000 | $25K | 2/12/2026 |
| Thomas Charles Heineman | ▲ Buy | Open Market | 12,132 | $10K | 2/12/2026 |
| Deborah Margaret Brown | ▲ Buy | Open Market | 25,000 | $21K | 2/12/2026 |
| Allison Hagerman | ▲ Buy | Open Market | 10,000 | $8K | 2/12/2026 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 40,000 | $34K | 2/12/2026 |
| Patricia S. Andrews | ▲ Buy | Open Market | 35,400 | $30K | 2/12/2026 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 60,000 | $50K | 2/11/2026 |
| Andrew Aromando | ▲ Buy | Open Market | 29,600 | $25K | 2/11/2026 |
| Jared Kelly | ▲ Buy | Open Market | 5,600 | $5K | 2/11/2026 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 100,000 | $104K | 1/16/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Oncolytics Biotech Activates All REO 033 Trial Facilities
Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.
Oncolytics Biotech Activates All REO 033 Trial Facilities. Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.